Nurix Therapeutics, Inc. (NRIX) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Nurix Therapeutics, Inc. (NRIX) stock forecast summary
On Oct. 14, 2026, NRIX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Nurix Therapeutics, Inc. is a mid-cap company with a market capitalization of $2.30B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/E Ratio of 7.79x is the lowest of the 16 peers that report one.
A per-ticker accuracy statistic for NRIX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NRIX included.
Follow NRIX freeNRIX price chart and AI forecast
How NRIX ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Nurix Therapeutics, Inc. (NRIX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | NRIX | Rank |
|---|---|---|
| Market Cap | $2.30B | 60/60 |
| P/E Ratio | 7.79x | 16/16 |
| P/B Ratio | 2.37x | 40/43 |
| EPS | $2.42 | – |
| Book Value/Share | $9.33 | – |
| Revenue/Share | $6.79 | – |
| FCF/Share | $3.56 | – |
Profitability & Margins
| Metric | NRIX | Rank |
|---|---|---|
| ROE | 30.4% | 5/33 |
| ROA | 24.7% | 2/39 |
| ROIC | 27.2% | 1/41 |
| Operating Margin | 41.1% | 5/33 |
| Net Margin | 41.8% | 4/33 |
| EBT Margin | 43.0% | 8/40 |
| Tax Rate | 4.4% | – |
Financial Health
| Metric | NRIX | Rank |
|---|---|---|
| Current Ratio | 8.44x | 11/50 |
| D/E Ratio | 0.23x | 32/43 |
| Financial Leverage | 1.23x | 33/43 |
| Working Capital | $973M | 29/50 |
Cash Flow
| Metric | NRIX | Rank |
|---|---|---|
| Operating Cash Flow | $379M | 20/49 |
| Free Cash Flow | $370M | 17/39 |
| Capital Spending | -$10M | 17/39 |
| FCF/Sales | 52.5% | 3/34 |
| CapEx/Sales | 1.4% | 25/34 |
Operational Efficiency
| Metric | NRIX | Rank |
|---|---|---|
| Asset Turnover | 0.59x | 10/38 |
| Receivables Turnover | 35.2x | 2/34 |
| Fixed Assets Turnover | 36.3x | 11/37 |
| Days Sales Outstanding | 10 days | 33/34 |
Income Statement
| Metric | NRIX | Rank |
|---|---|---|
| Total Revenue | $705M | 28/39 |
| Operating Income | $289M | 12/41 |
| Net Income | $294M | 15/40 |
| R&D Expense | $334M | 29/48 |
Dividend & Shareholder Information
| Metric | NRIX | Rank |
|---|---|---|
| Shares Outstanding | 104M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.10B | 92.3% of assets |
| Cash & Short-term Investments | $720M | 60.2% of assets |
| Accounts Receivable | $20M | 1.7% of assets |
| Total Liabilities | $227M | 19.0% of assets |
| Short-term Debt | $98M | 8.2% of assets |
NRIX quarterly financials and insider trading
Nurix Therapeutics, Inc. (NRIX) industry peers
Companies classified under the same SEC industry code as Nurix Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NRIX Nurix Therapeutics, Inc. | ▶ | $2.30B |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.85B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.50B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▲ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $31.26B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ZLAB Zai Lab Ltd | ▼ | $27.60B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.74B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.59B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $20.15B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where NRIX sits on the market map
Nurix Therapeutics, Inc. (NRIX) stock news
Loading...
Nurix Therapeutics, Inc. (NRIX) stock forecast FAQ
What is the Nurix Therapeutics, Inc. (NRIX) stock forecast?
On Oct. 14, 2026, NRIX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Nurix Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for NRIX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nurix Therapeutics, Inc. forecasts updated?
Nurix Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Nurix Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, NRIX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.